Results 151 to 160 of about 11,416 (241)

Nucleotide Metabolism in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao, Yiyu Zeng, Yike Xu, Shu Rao, Mouna Khouchani, Hassna Soummane, Jingyi Li, Rui Liu   +7 more
wiley   +1 more source

Clinical outcomes of carbon-ion radiotherapy for residual or recurrent hepatocellular carcinoma after transarterial chemoembolization. [PDF]

ESMO Gastrointest Oncol
Sekiguchi Y, Shibuya K, Tomogane S, Miyasaka Y, Kakizaki S, Okamoto M, Araki K, Shirabe K, Ohno T.   +8 more
europepmc   +1 more source

Radiobiology studies of gold nanoparticle‐enhanced radiosensitization in proton therapy

Medical Physics, Volume 53, Issue 8, August 2026.
Abstract Background Approximately 50%$\%$ of newly diagnosed cancer patients worldwide receive radiotherapy, most commonly with X‐rays. Proton therapy has emerged as a promising alternative, offering complementary advantages over conventional X‐rays due to its highly localized energy deposition at the Bragg peak, thereby reducing radiation exposure to ...
N. Fuster‐Martínez, D. H. Saucedo‐Cuberes, M. C. Jiménez‐Ramos, D. Esperante, J. M. Espino, J. Fuster, J. F. Belén‐Aguilar, L. González‐López, P. Huertas, S. Jimeno, I. Mingarro, D. Pascual, D. Suárez‐García, M. J. García‐Murria   +13 more
wiley   +1 more source

Carbon Ion Radiotherapy for Prostate Cancer

Carbon Ion Radiotherapy for Prostate Cancer
NIRS-MedAustron Jojint Symposium on Carbon Ion Therapy in ...
openaire   +1 more source

Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer-Achieving higher precision treatment. [PDF]

J Appl Clin Med Phys
Nagata J, Kusano Y, Komori M, Takayama Y, Kurokawa S, Ito A, Kamada T, Yoshida D, Kawashiro S, Katoh H.   +9 more
europepmc   +1 more source

An ion treatment planning framework for inclusion of nanodosimetric ionization detail through cluster dose

Medical Physics, Volume 53, Issue 8, August 2026.
Abstract Background Nanodosimetry relates the cumulative or statistical moments of Ionization Detail (ID) with biological endpoints of relevance to cancer radiotherapy using charged particles. This association suggests to develop an additional physics‐detailed layer of modeling that may complement biological modeling and treatment planning.
Simona Facchiano, Ramon Ortiz, Remo Cristoforetti, Naoki D‐Kondo, Oliver Jäkel, Bruce Faddegon, Niklas Wahl   +6 more
wiley   +1 more source

Exploratory case series of conversion to carbon ion radiotherapy after systemic therapy in advanced hepatocellular carcinoma. [PDF]

Int Cancer Conf J
Anzai H, Miwa C, Ogasawara S, Fujiya M, Kurosaki H, Tsuchiya T, Yoshino R, Katayama K, Sawada M, Akatsuka T, Izai R, Yonemoto T, Yumita S, Koroki K, Inoue M, Nakamura M, Kanogawa N, Nakamoto S, Makishima H, Shinoto M, Wakatsuki M, Yamada S, Ishikawa H, Kato J.   +23 more
europepmc   +1 more source

Photon minibeam‐based LATTICE radiotherapy for small and medium‐sized tumors: A dosimetric planning study

Medical Physics, Volume 53, Issue 8, August 2026.
Abstract Background Lattice radiotherapy (LRT) is a spatially fractionated technique that delivers three‐dimensional high‐dose vertices within tumors. However, conventional LRT is constrained by geometric limitations when applied to small and medium‐sized tumor volumes, primarily due to the large beam sizes that restrict optimal lattice pattern ...
Wei Wu, Nimita Shinde, Jiaxin Li, Isabelle Vanhaezebrouck, Kai Jiang, Yuting Lin, Qiang Li, Hao Gao   +7 more
wiley   +1 more source

MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial. [PDF]

JHEP Rep
Ogasawara S, Koroki K, Makishima H, Wakatsuki M, Takahashi A, Fujiya M, Yumita S, Nakagawa M, Kanzaki H, Kobayashi K, Inoue M, Nakamura M, Kanogawa N, Kondo T, Nakamoto S, Kurokawa T, Ozawa Y, Inaba Y, Paritala S, Chen J, Lee J, Hoshida Y, Hanaoka H, Yamada S, Ishikawa H.   +24 more
europepmc   +1 more source

Estimating the Sodium Content: A Case Series of Benign and Malignant Renal Tumours Using 23Na‐MRI at 3 T

NMR in Biomedicine, Volume 39, Issue 8, August 2026.
23Na‐MRI at 3 T was applied to estimate TSC in patients with kidney tumours of different pathologies, which are indistinguishable on conventional imaging methods. The apparent TSC was significantly higher in renal oncocytomas (benign) compared to chromophobe renal cell carcinomas (malignant): 162 ± 58 mM vs. 71 ± 2 mM (p < 0.05).
Ines Horvat‐Menih, Jonathan R. Birchall, Maria J. Zamora‐Morales, Alice Bebb, Joshua D. Kaggie, Frank Riemer, Andrew B. Gill, Andrew N. Priest, Marta Wylot, Iosif A. Mendichovszky, Anne Y. Warren, James Jones, James N. Armitage, Thomas J. Mitchell, Grant D. Stewart, Mary A. McLean, Ferdia A. Gallagher   +16 more
wiley   +1 more source